Holen Sie sich die Stockscreener-App
1.65
13.01%
0.19
Handel nachbörslich:
1.65
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CTXR?
Forum
Prognose
Aktiensplit
Citius Pharmaceuticals Inc Aktie (CTXR) Neueste Nachrichten
Is Citius Pharmaceuticals Inc. a good long term investmentFree Stock Market Knowledge Sharing - Autocar Professional
What analysts say about Citius Pharmaceuticals Inc. stockRecord-setting profit potential - jammulinksnews.com
What drives Citius Pharmaceuticals Inc. stock priceFree Real-Time Stock Data - jammulinksnews.com
Citius Pharmaceuticals Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com
Citius Oncology Announces Closing of $9.0 Million Public Offering - Eastern Progress
Citius Oncology closes $9 million public offering to support LYMPHIR - Investing.com Australia
Citius Oncology closes $9 million public offering to support LYMPHIR By Investing.com - Investing.com Nigeria
Citius Oncology Raises $9M in Public Offering for LYMPHIR Commercialization - AInvest
Citius Oncology Announces Closing Of $9.0 Million Public Offering - Barchart.com
Citius Oncology Announces Pricing Of $9M "Reasonable Best-Efforts" Public Offering Of 6,818,182 Shares Of Common Stock And Warrants To Purchase Shares Of Common Stock At A Public Offering Price Of $1.32 Per Share - 富途牛牛
Cencora distribution deal boosts Citius shares - MSN
Citius Pharmaceuticals shares fall 1.34% after-hours following Citius Oncology's public offering. - AInvest
Citius Oncology Announces Pricing of $9.0 Million Public Offering - Finansavisen
Citius Oncology (CTOR): Is LYMPHIR's Launch Priced for Success? - AInvest
Citius Oncology: Is A Lymphir Launch Coming Too Late? - Seeking Alpha
Citius Pharmaceuticals (CTXR) Surges on New Distribution Deal - GuruFocus
Citius Oncology stock rises after expanding LYMPHIR distribution network By Investing.com - Investing.com Nigeria
Citius Oncology stock rises after expanding LYMPHIR distribution network - Investing.com Australia
Citius Oncology Expands Lymphir Distribution With Cencora - MarketScreener
Citius Oncology expands distribution network for LYMPHIR with Cencora - Investing.com Australia
Citius Oncology expands distribution network for LYMPHIR with Cencora By Investing.com - Investing.com Canada
Citius stock gains on Cencora distribution deal (CTXR:NASDAQ) - Seeking Alpha
Pre-market Movers: KAPA, CYCC, SONN, RANI... - RTTNews
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora - WV News
Citius Pharmaceuticals Soars 10.18% on Nasdaq Compliance - AInvest
Citius Pharmaceuticals' Strategic Financing: Balancing Dilution Risks with LYMPHIR's Commercial Potential - AInvest
Citius Oncology Plans Stock Offering; Shares Down - MarketScreener
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) On The Verge Of Breaking Even - simplywall.st
Citius Pharmaceuticals regains Nasdaq compliance - MSN
Citius Pharmaceuticals Regains Nasdaq Compliance - The Globe and Mail
CTXR SEC FilingsCitius Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Citius Pharmaceuticals regains Nasdaq compliance after 10-day streak - Investing.com
Citius Pharmaceuticals regains Nasdaq compliance after 10-day streak By Investing.com - Investing.com UK
Citius Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement - 富途牛牛
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - Finansavisen
Citius Pharmaceuticals: LYMPHIR Launch Ignites High-Growth Potential in CTCL Market - AInvest
Citius Pharmaceuticals Prepares for Q2 2025 Commercial Launch of FDA-Approved Cancer Drug LYMPHIR - Insider Monkey
4.91%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):